Clinical Trial: Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07622771) titled 'Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial' on May 28.

Brief Summary: To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Rectal Cancers

Intervention: COMBINATION_PRODUCT: Adalimumab+NALIRIFOX->Short course radiotherapy ->Adalimumab+NALIRIFOX

Short course radiotherapy, 5 * 5Gy, once a day, 5Gy each time, for 5 days; Adalimumab 1200 mg , D1, q2w, 2 cycles ...